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Background: It has recently become evident that activating/inhibitory cell surface immune receptors play a critical
role in regulating immune and inflammatory processes in the central nervous system (CNS). The immunoreceptor
CD300f expressed on monocytes, neutrophils, and mast cells modulates inflammation, phagocytosis, and outcome
in models of autoimmune demyelination, allergy, and systemic lupus erythematosus. On the other hand, a finely
regulated inflammatory response is essential to induce regeneration after injury to peripheral nerves since
hematogenous macrophages, together with resident macrophages and de-differentiated Schwann cells,
phagocyte distal axonal and myelin debris in a well-orchestrated inflammatory response. The possible roles
and expression of CD300f and its ligands have not been reported under these conditions.
Methods: By using quantitative PCR (QPCR) and CD300f-IgG2a fusion protein, we show the expression of CD300f and
its ligands in the normal and crush injured sciatic nerve. The putative role of CD300f in peripheral nerve regeneration
was analyzed by blocking receptor-ligand interaction with the same CD300f-IgG2a soluble receptor fusion protein in
sciatic nerves of Thy1-YFP-H mice injected at the time of injury. Macrophage M1/M2 polarization phenotype was also
analyzed by CD206 and iNOS expression.
Results: We found an upregulation of CD300f mRNA and protein expression after injury. Moreover, the
ligands are present in restricted membrane patches of Schwann cells, which remain stable after the lesion.
The lesioned sciatic nerves of Thy1-YFP-H mice injected with a single dose of CD300f-IgG2a show long
lasting effects on nerve regeneration characterized by a lower number of YFP-positive fibres growing into
the tibial nerve after 10 days post lesion (dpl) and a delayed functional recovery when compared to PBS- or
IgG2a-administered control groups. Animals treated with CD300f-IgG2a show at 10 dpl higher numbers of
macrophages and CD206-positive cells and lower levels of iNOS expression than both control groups. At
later time points (28 dpl), increased numbers of macrophages and iNOS expression occur.
Conclusions: Taken together, these results show that the pair CD300f ligand is implicated in Wallerian
degeneration and nerve regeneration by modulating both the influx and phenotype of macrophages.
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Although axons in the peripheral nervous system (PNS)
have the capacity to regenerate and reach distal targets
after a mechanical injury, functional recovery is usually
not complete [1]. Successful axonal regeneration and
functional reinnervation depends on different factors
such as severity and site of nerve injury, age of the sub-
ject, and the distance that axons have to grow until they
reach distal targets, among others [2, 3].
After a peripheral nerve injury, the distal portion of the
nerve undergoes progressive degeneration in a process
called Wallerian degeneration (WD) [4]. While WD in the
PNS is fast, taking 14–21 days to clear axonal and myelin
debris, it is dramatically slow in the central nervous sys-
tem (CNS) [5]. This fact has suggested that slow or defi-
cient myelin and debris clearance from the injury site
could create an inhibitory environment for axonal regen-
eration. Accordingly, Wlds mutant mouse with a delayed
WD shows impairment of axonal regeneration [6, 7].
Thus, endogenous or therapeutic compounds increasing
the speed of WD might enhance axonal regeneration and
target reinnervation. WD begins with axonal degener-
ation, followed by myelin ovoid breakdown and myelin
clearance by Schwann cells and resident and infiltrating
macrophages [8, 9]. The recruitment of resident macro-
phages to the injury site starts within hours while the infil-
tration of macrophages from blood begins 2–3 days after
injury and peaks between 7 and 14 days [10, 11]. Finally,
myelin clearance is complete from 8 to 14 days after nerve
injury [12]. Some authors have classified WD in a two-
stage process: the first one, an inflammatory process when
pro-inflammatory cytokines such as IL-1β and TNFα are
produced mainly by resident macrophages and Schwann
cells, and a second stage of WD which aims at resolution
of inflammation with secretion of anti-inflammatory cyto-
kines such as IL-10 by infiltrated macrophages and
Schwann cells [13–16]. New insights into macrophage
activation related to macrophage polarization and their
pro-inflammatory or anti-inflammatory responses have
been reported [17, 18], and recently macrophages have
been classified as M1 or “classically” activated macro-
phages and M2 or “alternatively activated” macro-
phages, depending on the profile of cytokines required
for their activation [19, 20]. Taken together, these data
suggest that macrophages involved in WD might be po-
larized to the M1 phenotype on the first stage and to
the M2 phenotype for the resolution of inflammation.
Different markers have been suggested to be representa-
tive of the different phenotypes, such as CD206 (man-
nose receptor) or arginase I for M2 and iNOS or IL-1β
for M1 phenotype [20, 21]. Despite this important
breakthrough in activated macrophage classification,
only few studies have been published describing the
M1/M2 macrophage phenotype after a peripheral nerveinjury [22, 23]. Overall, the differences seen between
macrophage phenotype in the PNS and CNS could con-
tribute to explain the differences between the effective
WD process in the PNS in comparison with the CNS
where WD is very slow and inhibitory factors for nerve re-
generation remain in the damaged tissue. Thus, modula-
tion of inflammation and macrophage polarization to a
M1-M2 phenotype may represent a strategy to pro-
mote regeneration in the PNS and the CNS. However,
additional studies are needed to firmly establish this
hypothesis.
Activating/inhibitory immune receptors like CD200R,
TREM2, and SIGLECs have been shown to mediate im-
portant functions in checkpoints for the modulation of
neuroinflammation [24, 25]. The CD300 family of activat-
ing/inhibitory receptors is composed in humans by six
members that are able to form complexes on the cell sur-
face through the interaction among their extracellular im-
munoglobulin domain [26–31]. Their combination in a
complex differentially modulates the signaling outcome,
suggesting a mechanism of how CD300 complexes could
regulate the activation of myeloid cells upon interaction
with their natural ligands [32]. All the CD300 family
members share an extracellular region comprising a single
Ig-like domain and were thought to have a myeloid
lineage-restricted pattern of expression. However, the ex-
pression of CD300f was recently observed in microglia,
oligodendrocytes, and neurons in vitro [33]. The im-
portance of this family of receptors is highlighted by the
fact that one of its members, CD300a, is the second
gene with strongest evidence for positive selection be-
tween human and chimpanzee [34]. Moreover, CD300a
and CD300f are among the genes with the highest
upregulation after a spinal cord traumatic injury [33].
The CD300 family contains two inhibitory receptors,
CD300a and CD300f, both displaying a long cytoplas-
mic tail with a variety of different tyrosine-based mo-
tifs, that are able to recruit phosphatases like SHP1
and SHP2 and therefore deliver inhibitory signals.
The most interesting difference between these mole-
cules, besides their different pattern of expression, is
the existence of two binding motifs for the p85 sub-
unit of PI3Kinase in the cytoplasmic tail of CD300f.
In fact, it has been shown that CD300f delivers
in vitro both inhibitory and activating signals, thus
revealing a remarkable functional duality of this re-
ceptor [28, 35–38]. However, in vivo CD300f has
shown to be mainly an inhibitory receptor, as shown
in CD300f knockout animals using the experimental
autoimmune encephalomyelitis (EAE) model of mul-
tiple sclerosis [39] and very recently in several models
of allergy [40] and systemic lupus erythematosus [36].
This latter study shows that mouse CD300f (CLM-1)
recognized outer membrane phosphatidylserine and
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phages derived from CD300f knockout mice deficient
for phagocytosis of apoptotic cells. Other recent reports
suggest the existence of other main ligands for mouse
CD300f, as phosphatidylcholine or ceramide [40, 41],
and for human CD300f (IREM1), as sphingomyelin [42].
Despite the importance of CD300f in the regulation of
inflammation and clearance of cell debris and apoptotic
cells, no data is available regarding the expression of
CD300f or its ligands in the normal and lesioned nerve
and its role in regeneration.
In the present work, we characterize peripheral nerve
expression of CD300f after a crush injury and the pres-
ence of its ligands. Moreover, by using soluble receptor
fusion protein CD300f-IgG2a, we show that the blockade
of the interaction between the immunoreceptor and its
ligands impairs axonal regeneration and modulates
macrophage M1/M2 phenotype.
Materials and methods
Animal surgery and treatment
Both male and female adult (8–12 weeks old) Thy1-
yellow fluorescent protein mice, line H (Thy1-YFP-H;
Jackson Laboratories, Bar Harbor, USA) [43], were used
in these studies. All experimental procedures were ap-
proved by the IPMon Animal Care Committee and con-
ducted according to international FELASA guidelines,
national law, and ethical guidelines (Uruguayan Animal
Care Committee).
The surgical procedure was carried out following ster-
ile precautions. Mice were anesthetized with ketamine-
xylazine (90–10 mg/kg) and the right sciatic nerve at the
mid thigh level was exposed. Treatments were per-
formed by direct injections at 45 mm from the tip of the
third digit in 2 μl of sterile PBS, using a fine glass micro-
pipette connected to a Hamilton syringe. Immediately
after the injection and at the same position, the nerve
was crushed in two different directions 30 s each time
with fine forceps. The crush site was labeled with lamp
black powder. The wound was closed with 5–0 monony-
lon Ethilon sutures (Ethicon) and disinfected. The sciatic
and tibial nerves and the plantar skin were harvested at
24 h, 3, 10, and 28 days post lesion (dpl).
All nerve injections were performed in 2 μl PBS and at
10 μg/ml concentration of the following products:
rCD300f-IgG2a (rat extracellular domain of CD300f
fused to mouse IgG2a protein) or purified mouse mye-
loma IgG2a (Invitrogen, Cat. N° 026200).
Histological and immunohistochemical procedures
At 10 and 28 days post lesion (dpl), mice were deeply
anesthetized with pentobarbitone and intracardially
perfused with saline followed by 4 % paraformalde-
hyde in 0.1 M phosphate buffer solution. The sciaticnerve, including its main tibial branch, was dissected
to the ankle level and harvested. A sciatic nerve seg-
ment 3 mm distal to the injury site was postfixed in
4 % paraformaldehyde for 3 h, transferred to 30 % su-
crose, and frozen for further immunohistochemistry
procedures. The tibial nerve was sampled in two, one
segment of approximately 14 mm was washed with
PBS 0.01 M and whole mounted on slides in Mowiol
mounting medium, whereas another segment of
2 mm at the ankle level was dissected out, postfixed
in 2 % glutaraldehyde in 0.1 M phosphate buffer, and
processed for embedding in Epon resin for semithin
section preparations.
The sciatic nerve was cut longitudinally in the cryo-
stat (8 μm thickness) and stored at −20 °C until used.
Non-specific antibody binding was blocked with PBS
0.01 M + 1 % Triton + 10 % fetal bovine serum for 1 h at
room temperature. Sections were then incubated over-
night at room temperature with the following primary
antibodies: rabbit anti-Iba-1 (1:3000; Wako 019-19741),
rat anti-mouse CD206 (1:500; Serotec MCA2235),
rabbit anti-iNOS (1:500; Calbiochem 482728), and rat
anti-mouse F4/80 (1:150; Serotec MCA497). Macro-
phages were also demonstrated using biotinylated Licoper-
sicon esculentum (tomato) lectin (6 μg/ml; L9389; Sigma-
Aldrich). After washes with PBS-Triton 1 %, sections were
incubated for detection with appropriate secondary anti-
bodies (Invitrogen) and DAPI. Controls were made to rule
out nonspecific staining by incubation without the pri-
mary antibody.
For the recognition of mouse CD300f ligand, immuno-
histochemical stainings using a soluble fusion protein
containing the extracellular domain of rCD300f fused to
the Fc region of the IgG2a mouse heavy chain or control
mouse IgG2a were performed (both at 10 μg/ml). The
studies were done in teased fibres and cryostat sections.
For immunohistochemistry of teased fibres, sciatic
nerves were freshly dissected out and immediately
immersed in 4 % paraformaldehyde in 0.1 M phosphate
buffer for 3 h. After washing with PBS, the perineural
sheath was removed and nerve bundles were separated
using a pair of fine needles. Teased fibres were blocked
with PBS 0.01 M+ 1 % Triton + 10 % fetal bovine serum
for 1 h at room temperature and then incubated with the
following primary antibodies: rabbit anti-MBP (1:100;
Sigma-Aldrich M3821), rat anti-S100 (1:200; Sigma-
Aldrich HPA006462), and rCD300f-IgG2a (10 μg/ml),
overnight at room temperature. After washes with PBS-
Triton 1 %, sections were incubated for detection with ap-
propriate secondary antibodies (Invitrogen) and DAPI.
For quantification of skin innervation, plantar pads of
the hindpaw were removed at 28 dpl and processed as de-
scribed [44]. Briefly, after being postfixed in 4 % parafor-
maldehyde and cryopreserved, 70-μm cryostat sections
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with PBS 0.01 M + 0.3 % Triton + 1 % normal goat serum
for 1 h at room temperature. Sections were then incu-
bated in primary rabbit antiserum against protein gene
product 9.5 (PGP9.5, 1:1000; Ultraclone) for 48 h at 4 °C.
After several washes, sections were incubated for detec-
tion with appropriate secondary antibodies for 24 h at
4 °C and mounted on gelatin-coated slides. Five sections
from each sample were used to quantify the number
and density of nerve fibres present in the epidermis of
the paw pads.
Tissue sections were examined using an Olympus
IX81 microscope and images of the longitudinal sections
were acquired at 20× with an AxioCam MRm Zeiss
camera attached to a computer for further counts and
imaging processing by using ImageJ software. Confocal
images of teased fibres were acquired using a Leica TCS
SP5 II confocal microscope.
Semithin sections (1 μm) were obtained from the tibial
nerve blocks. Images of whole tibial nerve cross section
were acquired at 10× with an AxioCam MRm Zeiss
camera attached to a computer, while sets of images
chosen by systematic random sampling of squares repre-
senting at least 30 % of the nerve cross-sectional area
were acquired at 100×. Measurements of the cross-
sectional area of the whole nerve as well as counts of
the number of myelinated fibres were carried out by
using ImageJ software.Flow cytometry
Cell surface expression of the CD300f (CLM-1) was
tested by indirect immunofluorescence following stand-
ard techniques using a monoclonal anti-CLM-1 from
hamster and the corresponding isotypic control [37, 39].
Cells from uninjured and crushed sciatic nerve were
analyzed by flow cytometry at 3, 10, and 28 dpl as
described previously [45] with some modifications.
Briefly, animals were perfused with PBS to eliminate
blood. Crushed sciatic nerves were harvested, cut in
little pieces, and passed through a cell strainer of 70 μm
and the cell suspension centrifuged. Samples were incu-
bated with anti-mouse CD16/CD32 (1:100; Biolegend,
Cat N°101319) for 15 min at 4 °C to block the nonspecific
binding of immunoglobulins to the Fc receptors. Cells
were incubated with CD45-PerCP (Biolegend), CD11b-
PE-Cy7 (Biolegend), F4/80-APC (eBioscience), and mono-
clonal hamster anti-CLM-1 antibody (5 ug/mL) which was
a generous gift from Genentech (San Francisco, CA) or an
isotypic control (armenian IgG hamster from Serotec, Cat
N° MCA2356), in PBS for 30 min at 4 °C. After washing in
PBS, cells were incubated with an anti-armenian hamster
IgG-FITC secondary antibody (Biolegend, Cat N°405502)
in PBS for 30 min at 4 °C (dilution 1:100). Samples wereanalyzed with BD FACSCanto II Flow Cytometer and
FlowJo Software (BD Biosciences).
Evaluation of axonal regeneration
Tibial nerves from crushed sciatic nerves at 10 dpl were
whole mounted onto microscope slides and coverslipped
in Mowiol mounting medium. The number of YFP-
positive fibres was visualized using an Olympus IX81
microscope. Regenerating axons were counted at 1-mm
increments along the length of the tibial nerve beginning
at 8–9 mm from the crush injury site. All evaluations
were conducted by a researcher blinded to the treatment
groups as described [46].
Functional evaluation
The walking track sciatic functional index (SFI) test was
also carried out to assess recovery of locomotor func-
tion. The plantar surface of the mouse hindpaws was
painted with black ink prior to crossing a runway. Foot-
prints corresponding to the operated and intact paws
were easily identified. The print length (PL) and the dis-
tance between the first and fifth toes (toe spread, TS)
and between the second and fourth toes (intermediate
toe spread, IT) were measured. The three parameters
were combined in the SFI [47] to quantify changes in
walking patterns. The SFI varies between 0 (for unin-
jured) and −100 (for maximal impaired gait). The walk-
ing track test was carried out prior to surgery to obtain
baseline scores and then on days 4, 7, 10, 14, 17, and 28
dpl to assess the recovery of locomotor function. A re-
searcher blinded to the treatment groups conducted all
evaluations.
Isolation of RNA and QPCR
Previous to nerve harvesting, animals were perfused with
ice-cold PBS to eliminate blood. Due to very low RNA re-
covery from each nerve, the RNA was isolated and purified
from pooled homogenized nerves (from 1 mm proximal to
6 mm distal to the crush, n = 6 per group as described in
[48] in TRIzol (SIGMA, T9424), and the aqueous phase
was further purified using the Nucleospin RNA II Kit
with RNase Free DNase treatment (Macherey Nagel
740955.50). RNA samples were reverse transcribed
using M-MLV reverse transcriptase (Invitrogen 28025–
013) and random primers. Quantitative PCR (QPCR) was
performed using the following TaqMan reagents from Invi-
trogen/Applied Biosystems: TaqMan Fast Advanced Mas-
ter Mix (1205919), exon-spanning probes for CD300f/
CLM1 (Mm00467508_m1), IL-1b (Mm01336189_m1),
iNOS (Mm00440502_m1), MRC1 (Mm00485148_m1),
and IL-10 (Mm00439614_m1). The relative expression
ratio is calculated using the real-time PCR efficiencies and
the crossing point deviation of an unknown sample versus
a control according to Pfaffl [49]. Eucariotic 18S RNA
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in the model to standardize each reaction run with respect
to RNA integrity and sample loading. QPCR was per-
formed using the Corbett Rotorgene 6000 apparatus
and software. Cycling conditions were 50 °C for 2 min,
95 °C for 10 min, followed by 45 cycles at 95 °C for 15 s
and 60 °C for 1 min. [48].
Production of rCD300f-IgG2a
Chinese hamster ovary (CHO-K1) cells were stably
transfected with pSecTag/mIgG2a constructs [26] and
positive cells were selected with 250 mg/mL of Zeocin
(Invivogen, San Diego, CA, USA). The chimerical pro-
tein was purified from the supernatant using a protein
A-sepharose column (GE Healthcare, Pittsburgh, PA,
USA) as described before [26].
Phagocytosis assay
Ten days after the crush injury and the different treat-
ments, mice were anesthetized and approximately
8 mm of the lesioned nerve distal to the injury site was
obtained, epineurium dissected and discarded, and in-
cubated in PBS + collagenase (2 mg/ml) for 30 min at
37 °C. After homogenization, single-cell suspensions
from each nerve in separate wells were plated for 2 h in
DMEM supplemented with 10 % fetal bovine serum and
penicillin 100 U/ml, streptomycin 100 μg/ml and in the
presence of fluorescent beads (1:1000; Life Technolo-
gies, F-8762). After several washes, cells were fixed in
4 % PFA and the number of beads per cell were quanti-
fied under epifluorescence microscope observation by a
treatment-blinded researcher.
Data processing and statistical analysis
All data are shown as mean ± standard error of the
mean (SEM). Statistical analysis of behavioral data (SFI)
was determined using two-way repeated measures
ANOVA followed by Bonferroni post hoc analysis. One-
way analysis of variance (ANOVA) followed by Tukey’s
post hoc analysis was used for experimental data with
more than two experimental groups. A value of p ≤ 0.05
was considered to be statistically significant.
Results
CD300f expression in the sciatic nerve after injury
Expression of the immune receptor CD300f in the sci-
atic nerve was assessed by QPCR and flow cytometry in
control uninjured and crush lesioned samples. Low
basal CD300f mRNA expression was detected; its levels
increased at 1 day post lesion (dpl), peaking at 3 dpl
and declining thereafter, showing at 28 dpl slightly
lower levels than at 1 dpl but still remaining high in
comparison with uninjured nerves (Fig. 1a). Protein ex-
pression of CD300f and several macrophage markers(F4/80, CD45, and CD11b) were analyzed by flow cy-
tometry in uninjured and crushed sciatic nerves at 3,
10, and 28 dpl (Fig. 1b–e). A small proportion of resi-
dent CD45+/CD11b+/F4/80+ macrophages expressed
CD300f in the uninjured nerve (Fig. 1e). After crush
sciatic nerve lesion, there was an increase in the total
number of CD45+/CD11b+/F4/80+ macrophages present
in the injured nerve in comparison with a non-injured
nerve. Nearly 40 % of these macrophages expressed
CD300f at 3 dpl, and the expression declined pro-
gressively to 28 dpl. Moreover, few F4/80 negative
and CD11b+/CD45+ positive cells at 3 and 10 dpl also
expressed CD300f, most probably representing neutro-
phils and maybe mast cells (not shown).
CD300f ligand is expressed in the PNS
In order to characterize the presence of the ligand of
CD300f in the PNS, we performed immunohistochemi-
cal studies using rCD300f-IgG2a fusion protein as de-
scribed [50] on both frozen sections and teased fibres.
Uninjured teased fibres from Thy1-YFP-H transgenic
mice showed a punctate staining pattern with rCD300f-
IgG2a, not co-localizing with the axonal cytoplasm
(Fig. 1f ). While no co-localization was observed at the
MBP-positive myelin domain of Schwann cells (Fig. 1g),
partial co-localization with the external limit of S100-
positive Schwann cell domain was apparent (Fig. 1h).
Frozen sections of crushed sciatic nerve were used in
order to assess the expression of the ligand after the in-
jury. At 10 dpl, no apparent difference was observed in
the staining for the ligand in comparison with an unin-
jured nerve (Fig. 1i, j). No staining was detected using
IgG2a negative control (Fig. 1k).
CD300f participates in axonal regeneration
In order to evaluate the role of CD300f in regeneration
after a crush nerve injury, the crushed sciatic nerve of
Thy1-YFP-H transgenic mice was injected with a single
dose of soluble CD300f-IgG2a at the moment of the in-
jury. CD300f receptor-ligand interaction blocked in this
way has been shown to render identical results com-
pared to CD300f knockout animals [39, 40]. Axonal re-
generation at 10 dpl was evaluated by counting the
number of YFP-positive fibres growing through the tibial
nerve as previously reported [46, 51]. In transgenic YFP-
H mice, approximately 3 % of myelinated peripheral
nerve fibres are YFP positive, with approximately 58 %
of them being sensory axons and 42 % motor axons [52].
Consequently, Thy1-YFP-H mice have provided a valu-
able tool for studies of Wallerian degeneration [53] and
nerve regeneration [46, 51, 52, 54]. When lesioned sci-
atic nerves were injected with CD300-IgG2a, a signifi-
cant lower number of regenerating axons growing long
distances were observed compared to both mIgG2a and
Fig. 1 Expression of CD300f and its ligand in normal and lesioned nerve. QPCR from lesioned nerve show time-dependent increased CD300f expression
(a, relative to unlesioned nerve = 1). b-c, representative flow cytometry profiles showing the selection of macrophages in the crushed sciatic nerve at 3
dpl (b, CD45+CD11b+; c, CD45+CD11b+F480+), and d, expression of CD300f in CD45+CD11b+F480+ cells in the crushed sciatic nerve at 3 dpl (black, only
secondary antibody-FITC; grey, hamster isotype control; green, hamster anti-CLM-1). e Quantification showing the percentage of macrophages expressing
CD300f in the uninjured nerve and at 3, 10, and 28 dpl. Note that CD300f peaked at 3 dpl declining thereafter. Confocal images of teased fibres from
adult sciatic nerves showed staining for the CD300f ligand (using CD300f-IgG2a), which did not co-localize with the axon (f, Thy1-YFP-H mice) nor with
the MBP-positive myelin domain of myelinating Schwann cells (g). Partial co-localization could be observed with the S100-positive non-myelinating
outer limit of the myelinating Schwann cells (h). The staining with CD300f-IgG2a in uninjured nerve (i) did not change at 10 dpl (j). IgG2a negative
control did no show any staining (k). Scale bars: b: 30 μm; c, d: 100 μm; e-g: 20 μm
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the recovery of function after crush injury by analyzing
the hindpaw prints to obtain the SFI. After crush sciatic
nerve injury, the SFI drops to −80 % whereas it recovers
by day 28 up to −20 % with no significant differences
when compared to pre-injury values. After CD300f-
IgG2a treatment, a strong tendency (p = 0.07) towards
delayed functional recovery was observed compared toFig. 2 (See legend on next page.)IgG2a control animals (Fig. 2c). A detailed study of re-
generated fibres was performed at 28 dpl by analyzing
the number of regenerated myelinated fibres counted in
semithin sections in the tibial nerve at the ankle level,
and no differences between groups were observed
(Fig. 2d). In addition, distal re-innervation was assessed
by counting the number of PGP9.5-positive fibres in the
epidermis. The number of PGP9.5-positive fibres was
(See figure on previous page.)
Fig. 2 CD300f-IgG2a slows down axonal regeneration at 10 days after a sciatic nerve crush injury. Confocal images of whole mount tibial
nerve at 18 mm distal from the crush site of uninjured or injured and injected nerves at 10 dpl (a). Thinner regenerating axons are seen
in the tibial nerve (IgG2a and CD300f-IgG2a) compared with uninjured nerves. The group treated with the soluble receptor CD300f-IgG2a
shows less axons growing distally through the tibial nerve than the IgG2a control group. b YFP-positive axons numbers are expressed as
the percentage of contralateral axons at the indicated distance from the crush site at 10 dpl (n = 8 animals per group; *p < 0.05 vs. PBS
and IgG2a). Representative footprints obtained from uninjured and at 10, 17, and 28 dpl are shown (c). The Sciatic Functional Index (SFI)
walking track analysis revealed a strong tendency (p = 0.07) towards delayed functional recovery after treatment with CD300f-IgG2a when
compared to IgG2a control animals (n = 8 mice per group). Representative micrographs of transverse sections of an uninjured sciatic
nerve and at 28 days after crush injury and injection of IgG2a or CD300f-IgG2a show regenerated axons with thinner myelin at 28 dpl
(d). Quantification shows a decreased number of myelinated axons in the tibial nerve with significantly fewer myelinated fibres in all
crush injured animals (*p < 0.05 vs. uninjured group). The analysis of skin innervation at 28 dpl by the quantification of the number of
intraepidermal nerve fibres in the plantar skin immunolabeled against protein gene product 9.5 (PGP 9.5) showed a significant reduced
number of nerve fibres after crush injury, but no differences were observed between treated groups (*p < 0.05 vs. uninjured group). Scale
bars: a, e 50 μm; d 10 μm
Peluffo et al. Journal of Neuroinflammation  (2015) 12:145 Page 8 of 15significantly lower in injured groups than in the contra-
lateral skin at 28 dpl but no differences were seen be-
tween treatments (Fig. 2e). Taken together, these data
show that a single injection of the soluble CD300f-IgG2a
transiently delayed the regeneration, followed by en-
dogenous compensations that achieve normal regener-
ation at longer time points.
Blocking CD300f/ligand interaction induced macrophage
accumulation and changes in phenotype
In order to understand the mechanism of impaired re-
generation by blocking CD300f function, we assessed the
level of inflammatory markers and macrophage infiltra-
tion and phenotype. QPCR from nerve samples at 1 dpl
showed increased mRNA for IL-1β, iNOS, CD206, and
IL-10 when compared to uninjured nerves (Fig. 3a).
However, no significant differences were observed after
the injection of CD300f-IgG2a or IgG2a. Moreover, the
blockade of CD300f/ligand interaction did not alter
CD300f mRNA at 1 dpl. Interestingly, later on at 10 dpl,
immunohistochemistry against the general macrophage
marker tomato lectin in the sciatic nerve distally to the
crush showed increased numbers of positive cells with
the typical morphology of phagocytic macrophages,
which were further increased by treatment with CD300f-
IgG2a (Fig. 3b, c). Similar results were obtained with
anti-Iba-1 general macrophage marker (not shown). At
28 dpl, phagocytic macrophages could still be seen in
the sciatic nerve although at lower numbers than at 10
dpl (Fig. 3c). However, in the group injected with
CD300f-IgG2a, macrophages remained at significantly
higher numbers than in the control group.
We further evaluated whether the blockade of the
interaction between CD300f and its ligand had an effect
in the phenotype of the macrophages that infiltrated into
the nerve. We performed immunohistochemistry against
the mannose receptor (CD206) as a marker of alternative
M2 macrophages and against iNOS as a marker of clas-
sical proinflammatory M1 macrophages. iNOS labelingwas significantly reduced in animals treated with
rCD300f-IgG2a at 10 dpl but increased at 28 dpl in com-
parison with the injured control group (Fig. 3d, e).
CD206 labeling of the uninjured and IgG2a-treated
nerves showed a low number of CD206-positive cells
scattered through the nerve without differences between
uninjured and injured nerves at 10 dpl. However, in the
group of animals injected with rCD300-IgG2a, there was
a significantly higher number of CD206-positive cells at
10 dpl (Fig. 3f, g). At 28 dpl, the injured control group
showed higher numbers of CD206-positive cells in com-
parison with uninjured nerves and control injured
nerves at 10 dpl but without significant differences be-
tween the injured control group and the rCD300f-
IgG2a-treated group. Interestingly, considering all the
experimental groups together, the number of regenerat-
ing YFP-positive fibres negatively correlated with the
number of CD206-positive cells at 10 dpl (Spearman’s
rank test, p = 0.02, r = −0.64). This correlation was not
observed at 28 dpl.
Tomato lectin has been widely used as a marker of
microglia/macrophages and endothelial cells in the
CNS [55, 56]. Here, we show that tomato lectin is also
a good marker for macrophages in the normal and le-
sioned nerve when compared to Iba-1 and F4/80
(Figs. 4 and 5). Tomato lectin labeling increased from 3
dpl peaking at 10–14 days post lesion (Fig. 4) as pub-
lished by other authors using other macrophages
markers such as F4/80 and CD11b [10, 11]. Tomato lec-
tin and Iba-1 labeled the very few resident macrophages of
the normal nerve (Fig. 4a–c). Interestingly, an important
heterogeneity of macrophages was observed after the le-
sion. Most infiltrated large foamy macrophages at all time
points were intensely stained with tomato lectin, Iba-1,
and F4/80 markers (Figs. 4d–l and 5). However, smaller
cells showed different combinations of stainings, in-
cluding tomato lectin-positive and Iba-1 and F4/80-
negative staining. This latter category would also include
the endothelial cells. Moreover, both Iba-1 and F4/80
Fig. 3 CD300f-IgG2a increases macrophage infiltration and induces their phenotypic change after a sciatic nerve crush injury. QPCR shows an
increase of several cytokines and CD300f at 1 dpl with no differences between treatments (a). Infiltrated macrophages stained by tomato lectin
show increased number at 10 and 28 dpl following CD300f-IgG2a treatment (b, c). The macrophage phenotype is altered after CD300f-IgG2a
treatment, showing decreased iNOS staining at 10 dpl and increased staining at 28 dpl (d, e: mean grey value). On the contrary, the number of
CD206-stained cells shows an important increase at 10 dpl (f, g), but no significant differences at 28 dpl. YFP-regenerated myelinated fibres can
be seen in green in b and f. (*p < 0.05 vs. uninjured and IgG2a treatment). Scale bar in b and e: 40 μm
Peluffo et al. Journal of Neuroinflammation  (2015) 12:145 Page 9 of 15stained small macrophages that remained unstained with
tomato lectin (Fig. 4d–i red arrows, Fig. 5 arrows). This
macrophage phenotype heterogeneity could also be ob-
served with M1/M2 markers like iNOS and CD206. Al-
though most iNOS and CD206 staining co-localized with
the big foamy tomato lectin and F4/80-positive macro-
phages (Fig. 5 arrowheads), round and smaller tomato
lectin-negative and F4/80-positive macrophages also
expressed iNOS or CD206 (Fig. 5 arrows). Taken together,these data show that all iNOS and CD206 staining was de-
tected inside tomato lectin, Iba-1, or F4/80-positive cells.
Phagocytosis after blockade of CD300f
To further characterize the phenotype of inflamma-
tory cells in the anti-regenerative milieu at 10 dpl in-
duced by CD300f-IgG2a, we analyzed the phagocytic
activity of nerve cells. Acutely isolated nerve cells
were incubated for 2 h with fluorescent beads and
Fig. 4 Tomato lectin stains most of the macrophages in the normal and injured nerve. Single focal plane confocal microscopy showed tomato
lectin staining for macrophages in the normal and lesioned nerve. Tomato lectin and Iba-1 labeled the very few resident macrophages of the
normal nerve (a-c, arrowhead) and meninges (a-c arrow). An increase of tomato lectin and Iba-1 staining was observed at earlier time points after
a crush injury (3 dpl), which peaked at 10 dpl and decreased by 28 dpl (d-l). Most macrophages were stained with both markers (a-l, arrowheads),
including big foamy macrophages and some smaller and round macrophages. Interestingly, some cells were only stained with tomato lectin (d-l, white
arrows) and other only stained with Iba-1 (d-l, red arrows). Scale bar: 20 μm
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ment of the nerve with CD300f-IgG2a at the time of
the lesion, induced 10 days later, increased phagocytic
activity of nerve cells when compared to IgG2a treat-
ment. A reduction in the percentage of cells with 0–1
phagocyted beads and an increase in the percentage
of cells with 6–10 phagocyted beads were observed
after CD300f-IgG2a treatment (Fig. 6).Discussion
In the present work, we show that both CD300f and its
ligands are present in the non-injured peripheral nerve,
and that CD300f mRNA and protein are increased after
a crush lesion. Interestingly, a single injection of the
CD300f-IgG2a soluble fusion protein into the injured
sciatic nerve delays both axonal regeneration at 10 dpl
and functional recovery but has no effects at long-term
Fig. 5 iNOS and CD206 stain a heterogeneous population of macrophages. Single focal plane confocal microscopy for iNOS or CD206 combined
with tomato lectin and F4/80 macrophage staining evidenced that most cells co-stain with tomato lectin and F4/80, and some of them are in
addition iNOS or CD206 positive (arrowheads). Moreover, there is a population of round and smaller F4/80-positive and tomato lectin negative
macrophages that also shows iNOS or CD206 staining (arrows). Scale bar: 20 μm
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a modulation in the number and phenotype of M1/M2
macrophages in the lesioned nerve.
Recent reports have shown that phospholipids as phos-
phatidylcholine or phosphatidylserine are ligands for CLM-
1, the mouse orthologue of CD300f [35, 36, 41]. Phosphati-
dylserine/CLM-1 interaction contributes to apoptotic cell
clearance and hence to dampen inflammation [35, 36]. Cer-
amide has also been described as a putative ligand for this
receptor, contributing to dampening inflammatory reac-
tions of mast cells in several allergy models by the activa-
tion of CLM-1 negative signaling [40]. The interaction of
activating/inhibitory immunoreceptors with lipids appears
to be a more general phenomenon [41]. For instance, some
gangliosides and 3-O-sulfo-β-d-galactosylceramide (C24:1)
are potential ligands for CD300b/CLM-7 [57]. In theFig. 6 CD300f-IgG2a increases phagocytosis at 10 days after a sciatic nerve
dpl show enhanced phagocytosis of fluorescent beads after CD300f-IgG2a
having phagocyted none or 1 bead and an increase in the number of cells
IgG2a treatment)central nervous system, staining of the brain and spinal
cord with rat or human CD300f-IgG2a showed a distinctive
punctuate pattern, mainly in oligodendrocytes of the white
matter [50]. Accordingly, we show here a similar punctuate
staining pattern with CD300f-IgG2a in peripheral nerves.
Interestingly, by using teased nerve fibres and Thy1-YFP-H
mice, we evidence the specific subcellular localization of
the CD300f ligands to what appears to be the outer cell
membrane of the non-myelinating S100-positive domain of
myelinating Schwann cells previously described [58] and
not to the MBP-positive myelin sheath or the axonal com-
partment. However, we cannot discard the possibility
that the ligand may also be present in non-myelinating
Schwann cells or some component of the extracellular
matrix. Although electron microscope procedures are
necessary to determine its precise location, our confocalcrush injury. Nerve cells acutely isolated from the injured nerve at 10
treatment compared to control IgG2a. A significant decrease of cells
having phagocyted 6–10 beads was observed (*p < 0.05 vs.
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outer non-myelin Schwann cell membrane [58]. The
normal presence of the ligands in Schwann cells and oli-
godendrocytes point to supplementary roles in addition to
the phosphatidylserine “eat me” signal or the ceramide-
induced signaling previously described. Other authors
have shown that CD200, the ligand for the inhibitory im-
mune receptor CD200R, is expressed in Schwann cells in
the intact nerve [59]. In the CNS, this receptor induces a
tonic anti-inflammatory signal contributing to set the
threshold and magnitude of proinflammatory signaling
[24, 60]. Whether the ligand of CD300f expressed on
Schwann cells and oligodendrocytes also contributes to
the maintenance of this tonic anti-inflammatory state is
an open question. Chang and co-workers showed that
CD200 is downregulated after crush injury in the site of
lesion [59]. They hypothesized that, after nerve injury,
CD200 is downregulated in order to decrease immuno-
suppression and enhance influx of macrophages and the
inflammatory response to eliminate myelin and axonal
debris. The ligands for CD300f do not decrease at least at
10 dpl, suggesting different signaling mechanisms for
these two receptors. Interestingly, despite intense inva-
sion of macrophages into the nerve, a very similar
staining pattern was observed for the CD300f ligands,
suggesting that macrophages do not bear the ligand.
In accordance, microglial cells in vitro did not stain
with CD300f-IgG2a [50].
Recent findings suggest that the anti-inflammatory
physiological state of most tissues is not only a passive
state resulting from absence of inflammatory stimuli but
an active condition that requires participation of several
molecules responsible for the suppression of potentially
inflammatory stimuli. Under this paradigm, a physio-
logical function for the ligands of inhibitory receptors
like CD200R, CD300a, or CD300f could be to contrib-
ute to the so-called “On” and “Off” signals [61]. “Off”
signals are constitutively present in the brain paren-
chyma and are expressed mainly by healthy neurons,
whereas “On” signals are expressed by endangered or
impaired neurons [62]. The integration of all the inhibi-
tory and activating inputs shapes the phenotype and re-
sponse of microglial cells or macrophages accordingly.
In fact, several activating and inhibitory receptors simi-
lar to CD300f like CD200R, TREM2, or SIGLECs have
been reported to be key regulators of microglial and
macrophage activation [24, 25]. Thus, these mecha-
nisms, including CD300f and its ligands, could also be
in place for the interaction of macrophages and
Schwann cells in the normal and injured PNS to regu-
late the inflammatory status.
CD300f has been reported to deliver both activating
and inhibiting signals [28, 35–37]. However, only inhibi-
tory signals have been found on monocytic cell lines. Forinstance, crosslinking CD300f in the human THP1
monocytic cell line inhibited proinflammatory cell acti-
vation induced by several TLR ligands through a SHP1-
and SHP2-mediated mechanism [63]. The role of CD300f
in the proinflammatory activation of primary human
monocytes/macrophages in vitro has not been reported.
Using CD300f-deficient mice in the EAE mouse model, it
was shown that CD300f acts as a negative regulator of
myeloid cell activity by suppressing the production of in-
flammatory cytokines, nitric oxide, and demyelination
[39], confirming the negative anti-inflammatory signal-
ing exerted by CD300f on monocyte/macrophages.
After nerve injury, we show that CD300f mRNA was in-
creased from 1 dpl, peaking at 3 dpl, and decreasing at
28 dpl. The expression of the protein was demonstrated
by flow cytometry. We found protein expression in a
subpopulation of macrophages in non-injured nerves
and also after a crush injury, where the expression
peaked at 3 dpl. Interestingly, we observed few F4/80
negative cells that showed CD300f expression, a staining
that could represent neutrophils or mast cells. Accord-
ingly, CD300f expression has also been shown in neu-
trophils [26, 31] and mast cells [40], both of which
participate in nerve injury and regeneration. The time
window of appearance of CD300f positive cells corre-
lates with the influx rate of monocyte/macrophages and
neutrophils into the lesioned nerve [11, 64, 65]. To as-
sess the possible role of CD300f and its ligands after a
peripheral nerve injury, we took advantage of the de-
scription that CD300f receptor-ligand interaction could
be blocked using CD300f-Fc fusion proteins, rendering
identical results than those observed in CD300f knock-
out animals. For example, in the EAE model, CD300f-Fc
worsened clinical scores to similar levels than CD300f
KO mice [39, 40]. Moreover, intradermal pretreatment
with CD300f-Fc enhanced passive cutaneous anaphyl-
axis responses in wild type but not in CD300f KO mice
[40]. These results suggest that the effect of CD300f-Fc
proteins is mediated by dampening CD300f signaling by
an uncoupling of CD300f and its ligand rather than by
directly activating signaling by the interaction of the sol-
uble CD300f-Fc with the ligand. Interestingly, we show
that dampening CD300f signaling using the soluble
CD300f-IgG2a fusion protein-induced accumulation of
macrophages that displayed an M2 alternative activation
phenotype including increased CD206 and decreased
iNOS expression. Whether this is a direct effect of
dampening macrophage CD300f signaling or an indirect
effect remains to be elucidated. Despite injection of the
soluble receptor CD300f-IgG2a at the moment of the le-
sion, no acute changes on mRNA for CD206, iNOS, IL-
1β, IL-10, or endogenous CD300f were observed at 1
dpl. This suggests a more complex and long lasting mech-
anism of Schwann cell and macrophage interactions
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layed regeneration observed. In addition to the modula-
tion of the proinflammatory phenotype, CD300f may also
contribute to dampen inflammatory reactions promoting
phagocytosis of apoptotic cells [36]. Phagocytosis of mye-
lin and cell debris is a critical component of WD and suc-
cessful regeneration [5]. The impaired regeneration after
the single injection of CD300f-IgG2a might be related to
inhibition of phagocytosis and thus delayed debris clear-
ance. Accordingly, at 10 dpl, when no CD300f-IgG2a re-
mains, the accumulation of debris may trigger the
increased phagocytosis of nerve cells observed here that
may be responsible for the delayed but successful regener-
ation at 28 dpl.
Despite the importance of macrophage phenotype in
WD and axonal regeneration, only a few reports [22, 23]
have described the expression of M1/M2 phenotypic cell
markers after nerve injury and repair. In a recent paper,
Ydens and colleagues made a description of the different
markers of M1 and M2 macrophages after nerve tran-
section and repair in mice, showing a rapid M2
polarization of macrophages after axotomy [22]. They
evaluated a high number of markers of inflammation in-
cluding iNOS, CD206, and IL-1β at different time points
after nerve injury and mainly by QPCR. In accordance
with our results, they observed a rapid fast induction of
mRNA for IL-1β and IL-10 at 1 dpl. Moreover, they ob-
served the upregulation of other M2 markers like Arg1,
Ym1, or TREM2. They also reported that the mRNA for
CD206 did not show changes at the different time points
evaluated (until 14 dpl). In accordance, we did not ob-
serve notable changes in CD206 mRNA at 1 dpl or in
protein level at 10 dpl in comparison with uninjured
nerves. However, we also analyzed longer time points
(28 dpl) to sample processes of resolution of the neuro-
inflammation and found an increase in CD206 staining
in comparison with both uninjured and 10 dpl control
injured sciatic nerves. This late increase might be a con-
sequence of signals aimed to resolve inflammation by
adjusting macrophage polarization towards a healing
phenotype. In relation to M1 macrophage polarization
after nerve injury, Ydens and colleagues did not show a
significant change in iNOS, IL-12p40, or INFγ mRNA
levels at the different time points post lesion studied.
However, in the present work, we have seen a significant
increase in the iNOS mRNA at 24 h after lesion and in
the iNOS protein at 10 and 28 dpl. These differences in
the results could be due to the type of nerve lesion
used between the two studies, i.e., nerve section or
nerve crush. Further experiments are needed to es-
tablish the effect of the different M1/M2 markers on
nerve neuroinflammation and regeneration. In this
line, we show that the manipulation of the CD300f/
ligand interaction induces impairment of regenerationassociated to important changes in M1/M2 markers.
After a sciatic nerve crush injury, a single injection of
CD300f-IgG2a significantly increased the number of to-
mato lectin-positive macrophages and CD206-positive
cells and decreased iNOS immunoreactivity at 10 dpl,
whereas an opposite effect was found at 28 dpl. These
data suggest that blocking CD300f-ligand interactions
not only contributes to an enhanced recruitment of
macrophages but also to a change in the phenotype of
normally recruited macrophages towards an early M2
phenotype, followed by a switch to a M1 phenotype of
some macrophages later on. Interestingly, Mokarram
and colleagues induced a nerve section followed by
tubulization repair and IL-4 or INFγ treatment to
polarize macrophages towards a M2 or M1 phenotype,
respectively. Only IL-4 but not INFγ treatment induced
increased Schwann cell migration, macrophage recruit-
ment, macrophage polarization towards M2 phenotype,
and regeneration [23]. In the absence of any treatment,
they reported a main macrophage polarization towards
an M1 phenotype at 21 dpl, while we show mainly a
polarization towards an M2 phenotype at 28 dpl. More-
over, Mokarram and colleagues reported that the in-
crease in CD206-positive cells at 21 dpl positively
correlated with regeneration, while we observe in fact a
negative correlation at 10 dpl and no correlation at 28
dpl. This apparent contradiction between both studies
may be explained by the different nerve injury models,
i.e., nerve crush versus section and tubulization, where
the neuroinflammatory conditions are different and
where the structural maintenance of the epi-, peri-, and
endoneurium has strong effects. Moreover, the treat-
ment with IL-4 may change fundamental endogenous
neuroinflammatory mechanisms influencing the final
outcome of regeneration observed.
Conclusions
Taken together, these results establish a role for CD300f in
peripheral nerve injury, involving this immune receptor
and its ligands in the regulation of neuroinflammation,
M1/M2 macrophage recruitment and polarization, and
nerve regeneration. Moreover, the ligands of CD300f most
probably located in Schwann cells may constitute critical
players that participate in Schwann cell-mediated inter-
action with macrophages. Further experiments are needed
to better understand the mechanisms of action of CD300f
in peripheral nerve neuroinflammation and regeneration
and the putative role of other CD300f-expressing cells as
mast cells or neutrophils. Moreover, additional work with
other markers of M1/M2 phenotype has to be performed
to unravel the phenotype of macrophages and their
function after a peripheral nerve injury and how the ab-
sence of CD300f signaling might influence the pattern
of inflammation. Finally, after a crush nerve injury,
Peluffo et al. Journal of Neuroinflammation  (2015) 12:145 Page 14 of 15macrophages that take part in the first stage of WD
(1–10 dpl) would be polarized mainly towards a pro-
inflammatory M1 phenotype whereas the resolution
of inflammation at later stages (15–30 dpl) would be
driven predominantly by M2 macrophages.
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